Background and purpose Increased tumour hypoxia is associated with a worse overall survival in patients with head and neck squamous cell carcinoma (HNSCC). The aims of this study were to evaluate treatment-associated changes in [ Results At baseline, tumour hypoxia was detected in 69 % (22/32) of the GTVs. During therapy, we observed a significant decrease in all image parameters. The HF decreased from 21.7 ± 19.8 % (baseline) to 3.6 ± 10.0 % (during treatment; P < 0.001). Only two patients had a HV > 1 cm 3 during treatment, which was located for >98 % within the baseline HV. During treatment, no significant changes in plasma CAIX or VEGF were observed, while osteopontin was increased. Conclusions [ 18 F]HX4-PET/CT imaging allows monitoring changes in hypoxia during (chemo)radiotherapy whereas the blood biomarkers were not able to detect a treatmentassociated decrease in hypoxia.
Introduction
Tumour cell hypoxia is known to promote resistance to cancer treatment, to increase tumour aggressiveness, and to be a prognostic factor for survival [1] . Non-invasive imaging of tumour hypoxia by means of positron emission tomography (PET) has been shown to predict loco-regional control and survival, and may be used to select patients for additional anti-hypoxia therapy [2] [3] [4] . In addition, PET imaging can be used to monitor the response to treatment. Previous studies using the hypoxia PET tracer [ ]FDG observed that the uptake changes (early) during (chemo)radiotherapy had a higher predictive value than pre-treatment measurements [3, 5] . Previously, Overgaard [6] showed that the modification of hypoxia during Electronic supplementary material The online version of this article (doi:10.1007/s00259-016-3429-y) contains supplementary material, which is available to authorized users.
radiotherapy results in better loco-regional control and survival in patients with a squamous cell carcinoma of the head and neck (HNSCC). However, stratifying patients undergoing ARCON (accelerated radiotherapy with carbogen and nicotinamide) based on their pre-therapeutic hypoxic status (pimonidazole staining) demonstrated that the benefit in loco-regional control was specifically observed for patients with initial tumour hypoxia before the start of treatment [7, 8] . The pimonidazole staining of a biopsy, however, can only provide information about local hypoxia before the start of treatment. Non-invasive hypoxia PET imaging, on the other hand, provides an opportunity to perform repeated tumour hypoxia measurements in 3-dimensions. Therefore hypoxia PET measurements may be used to select patients likely to have a benefit from additional anti-hypoxia therapy.
One of the hypoxia PET tracers to visualize and quantify tumour hypoxia is the 2-nitroimidazole3-
18 F]HX4. In previous pre-clinical studies [
18 F]HX4 was validated as a hypoxia tracer, and the repeatability of the tracer uptake was assessed [9, 10] . In addition, in patients with non-small cell lung cancer (NSCLC), [ 18 F]HX4 showed promising results and was shown to provide additional value to the metabolic PET tracer [ 18 F]FDG [11, 12] . In this paper, we will investigate the potential of this tracer to detect treatment-associated changes in hypoxic tumour status in patients with HNSCC.
Another method to obtain information on tumour hypoxia may be the measurement of hypoxia-related proteins or enzymes in plasma. Potential relevant hypoxia markers are plasma osteopontin, carbonic anhydrase IX (CAIX), and vascular endothelial growth factor (VEGF). Osteopontin is activated under hypoxic conditions and is inversely correlated with the PO 2 value of the tumour [13] . In addition, plasma osteopontin is a significant predictor for the response to radiotherapy in patients with head and neck cancer [14] . CAIX expression is upregulated under the influence of tumour hypoxia. Also, in patients with NSCLC, a high level of plasma CAIX was associated with a shorter overall survival [15] . Last, hypoxia activates hypoxia inducible factor (HIF-1), which induces a high expression of VEGF, the primary cytokine related to angiogenesis. VEGF may, therefore, serve as an indirect marker of tumour hypoxia. These three markers might have the potential to stratify patients based on their hypoxic tumour status.
The aims of this study were to evaluate the changes in hypoxia during treatment in patients with HNSCC, the spatial stability of the uptake pattern, and the presence of plasma osteopontin, CAIX, and VEGF in relationship to hypoxia imaging.
Materials and methods

Patients
Between January 2012 and October 2014, we included 20 patients in this imaging study. Patient, tumour, and treatment characteristics are shown in Table 1 . The study was approved by the Ethical Review Committee of Maastricht University Medical Centre and registered on clinicaltrial.gov (NCT01347281). All patients provided written informed consent before study entry.
PET/CT imaging [ 18 F]HX4 was produced as described in previous publications [9, [16] [17] [18] . After intravenous administration of an average (±SD) dose of 378 ± 84 MBq [
18 F]HX4, PET/CT imaging was performed at 1.5, 3, and 4 h post-injection (p.i.) for 15, 15, and 20 min, respectively, for a single bed position centred around the primary tumour. After ten patients, an interim analysis showed highest contrast at the imaging time-point at 4 h p.i., and this was used from then onwards.
[
18 F]HX4 PET/CT scans were acquired before the start of external beam radiotherapy and during the radiation treatment; after an average (±SD) dose of 21 ± 2 Gy using a Biograph 40 PET/CT scanner (Siemens Healthcare, Erlangen, Germany). Scatter and attenuation corrections were applied, PET images were reconstructed using OSEM 2D (Ordered Subset Expectation Maximization, four iterations, eight subsets) and a Gaussian filter of 5 mm. Imaging was performed in radiotherapy position, with the patient positioned on a flat table top using an immobilization mask and a movable laser alignment system.
Image analysis
The gross tumour volume of the primary lesion (GTV prim ) and involved lymph nodes (GTV ln ), were delineated on the [ 18 F]FDG PET/CT, used for radiotherapy planning purposes, by two experienced radiation oncologists in consensus. These contours were copied to the [ 18 F]HX4 PET scan at baseline and during treatment by rigid registration. Maximum and mean standardized uptake values (SUV max and SUV mean ), were determined within the GTVs. In addition, the maximum tumour-to-muscle ratio (TMR max ), was calculated, defined as the SUV max in the tumour divided by the SUV mean in the trapezius muscles ( Supplementary Fig. 1 ). The hypoxic fraction (HF) and hypoxic volume (HV) were defined as the fraction or volume of the GTV with a TMR larger than 1.4.
To evaluate the spatial location of the [ ]HX4 uptake before and during radiotherapy was performed to compare spatial uptake patterns for both GTV prim and GTV ln .
Blood biomarker analysis
For all patients, blood samples were collected before and during (chemo)radiotherapy on the day of the [ 18 F]HX4 PET/CT scan. All blood biomarkers were measured in EDTA plasma. Samples were analysed simultaneously in a certified laboratory, using commercially available kits. CAIX was measured by a sandwich-type immunoassay that uses a mouse monocolonal capture antibody (V10) and a biotinylated mouse monocolonal antibody (M75) as detector (Nuclea Diagnostic Laboratories LLC, Cambridge, MA). Osteopontin and VEGF were measured by an ELISA method. A monoclonal antibody specific for osteopontin/VEGF was pre-coated onto the microplate and an enzyme-lined polyclonal antibody specific for osteopontin /VEGF was used as detector (R&D Systems (Minneapolis, MN).
To compare the plasma hypoxia markers with the [ 18 F]HX4 uptake in the GTV prim and GTV ln , we hypothesize that these markers reflect the uptake in all lesions within one patient. Therefore, the image parameters of multiple GTVs were combined, providing one SUV max and TMR max (the maximum of the present lesions). The hypoxic volumes were summed and for the SUV mean a weighted average was calculated using:
Statistical analysis
For all parameters, mean ± 1 standard deviation (SD) are reported. Non-parametric tests were used to determine significant differences in image and blood plasma parameters (Wilcoxon signed rank test) and to evaluate correlations between imaging parameters and blood parameters (Spearman's correlation coefficient; R s ). Linear regressions were performed to quantify the voxel-wise comparison, and a Pearson correlation coefficient (R p ) was calculated. A p-value < 0.05 was assumed to be statistically significant.
Results
In this study we analysed the [ F]HX4 PET scan during radiotherapy was not performed due to the patient's preference or health status. Eleven patients had involvement of the lymph nodes (GTV ln ), which were separately analysed from the primary lesion (GTV prim ). The average lesion sizes for GTV prim was 5, 3 , and 4 h p.i. In their lesions (10 GTV prim and 9 GTV ln ) we observed a significant increase in the TMR max from 1.5 h (1.5 ± 0.3) to 3 h p.i. (1.7 ± 0.4; P < 0.01), and from 3 to 4 h p.i. (1.8 ± 0.6; P = 0.02) (Fig. 1) . Therefore, [ We observed a significant correlation between the image parameters measured at baseline and during treatment: SUV mean (R s = 0.66, P < 0.001), SUV max (R s = 0.63, P < 0.001), TBR max (R s = 0.57, P < 0.01), HF (R s = 0.56, P < 0.01), HV(R = 0.52, P < 0.01). Taking into account the hypoxic lesions (GTV prim and GTV ln ), with a [ 18 F]HX4 PET/CT scan at baseline and during treatment (N = 17), we observed a significant decrease in all image-derived parameters during therapy (Table 2 ; Fig. 2 ). This decrease was independent of the given treatment (Supplementary Table 1 Only one non-hypoxic lesion (TBR = 1.37, HF = 0) at baseline, changed its hypoxic status during treatment. However, The TBR max increased only from 1.37 at baseline to 1 
Blood biomarkers
At baseline (N = 20) we measured an average concentration of 57 ± 26 ng/ml osteopontin, 190 ± 120 pg/ml CAIX, and 85 ± 67 pg/ml VEGF. There was no inter-correlation between t h e d i f f e r e n t p l a s m a p a r a m e t e r s . D u r i n g (chemo)radiotherapy (N = 17), a non-significant decrease in CAIX (173 ± 97 pg/ml; P = 0.45) and VEGF (75 ± 67 pg/ml; P = 0.74) was observed, whereas the increase in osteopontin was significant (65 ± 31 pg/ml; P = 0.04; Supplementary  Fig. 2 ).
Relationship blood biomarkers and [ 
Discussion
In this study we evaluated tumour hypoxia with [
F]HX4
PET in patients with HNSCC before the start of (chemo)radiotherapy and during treatment, with the aim to monitor treatment response and evaluate the spatial variability of the [ 18 F]HX4 uptake. In addition, the concentration of blood hypoxia markers (osteopontin, CAIX, and VEGF) was evaluated at baseline and during treatment. Last, the interdependence between hypoxia PET imaging and hypoxiarelated blood biomarkers was investigated.
Before the start of (chemo)radiotherapy, we observed tumour hypoxia in the majority of primary HNSCC and metastatic lymph nodes. However, in most of these lesions, hypoxia disappeared during the course of treatment, regardless of the chosen treatment; radiotherapy alone or in combination with cisplatin or cetuximab. The decrease of hypoxia during treatment has been described in several studies [3, [19] [20] [21] . Lee et al. [19] showed with [ 18 F]FMISO PET imaging a decrease in detectable tumour hypoxia from 90 % (18/20 patients) at baseline to 11 % (2/18) after 4 weeks of chemoradiotherapy. In addition, Servagi-Vernat et al. [20] observed a decrease of the [ 18 F]FAZA PET uptake (SUV max and HF) in all patients during chemoradiotherapy, which was recently confirmed by Bollineni et al. [21] . From our current results and the previous literature, we can conclude that in patients with HNSCC, hypoxia decreases during treatment, indicating tumour reoxygenation. Nevertheless, also a decrease in cell number, changes in vasculature, or perfusion could contribute to the altered hypoxia PET uptake.
Additionally, our results show that the patients with a high uptake at baseline have the highest chance of persistent hypoxia during treatment. These patients may benefit most from anti-hypoxia therapy during the entire course of treatment. For the other cases, the addition of anti-hypoxia therapy will probably have the largest therapeutic effect when given prior to, or during the first weeks of treatment. Since after this period, the PET imaging has already shown its potential to monitor the response to the antihypoxia treatment with TH-302 [22] . The ability to monitor the response to anti-hypoxia treatment with non-invasive imaging provides the potential to adapt the anti-hypoxia treatment based on the (changing) lesion characteristics.
Another frequently discussed method to target resistant tumour volumes is by giving a radiation boost. Previous studies have shown that it is technically feasible to provide a radiotherapy boost to hypoxic or metabolically active tumour subvolumes, defined on PET [4, [23] [24] [25] . For this purpose, information on the spatial repeatability of the hypoxia PET uptake and its stability during treatment is essential. In our current data-set only two lesions showed a significant amount of tumour hypoxia during treatment, with a spatially stable localization in comparison to the baseline scan. Where Bittner et al. [26] reported a geographically stable localization of the [ 18 F]FMISO PET uptake during chemoradiotherapy, Nehmeh et al. [27] , Lin et al. [27] , and Servagi-Vernat et al. [20] reported changes in the distribution of hypoxia during treatment, and, therefore, adaptive radiotherapy based on serial hypoxia PET imaging was recommended.
Serial hypoxia PET imaging during treatment may provide additional information for response prediction. In a preclinical setting, micro-environmental parameters (hypoxia, perfusion) during treatment had a better potential to predict outcome after radiotherapy [28] . This finding was confirmed in a clinical study by Zips et al. [3] in 25 patients with HNSCC. The authors found a significant correlation between [ 18 F]FMISO-PET imaging before and during chemoradiotherapy and local progression free survival, and tumour hypoxia during treatment was of higher prognostic relevance. In our study, accrual is ongoing and the assessment of hypoxia in relationship to outcome will be performed as data have matured.
We hypothesized that blood biomarkers could also be used to monitor treatment response, because previous studies have showed that blood biomarkers have the potential to predict response to treatment [29] . For example, a high concentration of plasma osteopontin was related to a higher amount of locoregional tumour failure in patients with HNSCC [14] . The blood biomarkers CAIX and VEGF, showed no significant changes during treatment and the osteopontin concentration was increased, while hypoxia PET imaging showed a clear reduction of the uptake in all patients. These results might be explained by the patient cohort. When comparing the plasma osteopontin levels of the patients in our current trial to the levels reported in the large randomized trial from Overgaard et al. [14] , we observed that all our patients should be assigned to the low or intermediate concentrations of plasma osteopontin. Also, in comparison to a study in 295 patients with advanced rectal cancer, our observed levels of osteopontin and CAIX were lower than their reported average values [29] . In addition, plasma osteopontin is not only influenced by hypoxia, it is also known to play a role in the immune regulation and stress response [30] . An elevated level of osteopontin was for example observed in patients with systemic inflammatory response syndrome or sepsis [31] . The given anti-cancer treatment might have induced an immune/stress response causing an elevated level of osteopontin. The observed concentration of plasma CAIX (190 ± 120 pg/ml) was higher than documented for 209 patients with NSCLC (mean: 45 pg/ml) or 58 healthy individuals (mean: 2.5 pg/ml) [15] . The concentration of plasma VEGF (85 ± 67 pg/ml) was similar to that observed in patients with NSCLC [32] and higher than reported in 50 healthy women (median: 37 pg/mL [33] ). Nevertheless, in the current population the blood biomarkers osteopontin, CAIX, and VEGF were not suitable to measure a hypoxia-related treatment response, which was measurable using [ 18 F]HX4-PET.
The correlation between the blood hypoxia markers and the [ 18 F]HX4 PET uptake was absent to weakly present. This was in agreement with the results previously published by several groups comparing hypoxia PET imaging to tissue or blood markers. Vercellino et al. [34] observed no correlation between the uptake of the hypoxia tracer [ 18 F]FETNIM and the plasma osteopontin concentration in 16 patients with cervical carcinoma. In addition, Gronroos et al. [35] found no correlation between hypoxia PET imaging using FETNIM and several tissue biomarkers in 15 patients with HNSCC. While in patients with newly diagnosed glioma, the preoperative [ 18 F]FMISO PET uptake was significantly, but weakly, correlated to the expression of VEGF in the tumour [36] . Although the current patient population is small, the results suggest that the tested blood biomarkers are not able to replace hypoxia PET imaging, or to pre-select patients for hypoxia PET imaging.
To conclude, hypoxia PET imaging with [ 18 F]HX4 is able to detect tumour hypoxia in patients with HNSCC; in addition, it can monitor a decrease of tumour hypoxia during treatment. In patients with persistent tumour hypoxia, a stable localization of the hypoxic volume was observed. This provides potential for radiotherapy dose escalation to the hypoxic volumes. The blood parameters osteopontin, CAIX, and VEGF were not able to detect a decrease in hypoxia during treatment. In addition, there was no correlation between the blood plasma parameters CAIX and VEGF and hypoxia PET imaging, while only a weak correlation was observed between [ 18 F]HX4 PET imaging and the osteopontin concentration during treatment. Based on the current data, we conclude that hypoxia PET imaging is the superior method to evaluate tumour hypoxia before and during treatment and cannot be replaced with the evaluated blood biomarkers.
